Xeltis Hemodialysis Access Conduit: aXess-E Study - Trial NCT06329310
Access comprehensive clinical trial information for NCT06329310 through Pure Global AI's free database. This phase not specified trial is sponsored by Xeltis and is currently Not yet recruiting. The study focuses on End Stage Renal Disease. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Xeltis
Timeline & Enrollment
N/A
Jul 01, 2024
Dec 01, 2026
Primary Outcome
Primary Patency rate,Freedom from device-related SAE
Summary
A prospective, single arm, non-randomized feasibility study to confirm the safety and
 performance of the Xeltis Hemodialysis Access conduit, aXess-E, in subjects older than 18
 years with end-stage renal disease, who plan to undergo hemodialysis for at least the first 6
 months after study access creation.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06329310
Device Trial